Pharmabiz
 

Sagent Pharma recalls atracurium besylate injection, USP, 50mg/5mL and 100mg/10mL from US market

Schaumburg, IllinoisThursday, February 26, 2015, 11:00 Hrs  [IST]

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, has announced the voluntary nationwide recall of two lots of atracurium besylate injection, USP, 50mg/5mL single-dose vials (NDC 25021-659-05) and four lots of atracurium besylate injection, USP, 100mg/10mL multi-dose vials (NDC 25021-672-10) manufactured by Emcure Pharmaceuticals Ltd. and distributed by Sagent.

Sagent has initiated this voluntary recall of atracurium besylate injection, USP, 50mg/5mL and 100mg/10mL to the user level due to FDA observations pertaining to aseptic and GMP practices at the manufacturer's site potentially impacting product sterility.  Non-sterility of a drug administered via the intravenous route has the potential to result in infections, which could be fatal, especially in patients who are immunocompromised. Sagent has transferred the manufacture of this product to its own facility and this product manufactured at the Sagent facility will not be impacted by the recall.

Segant announed that the company is not aware of any adverse patient events resulting from the use of the subject product lots.

The lot numbers being recalled are VATA012, VATA015 (50mg/5mL) and VATB012, VATB013, VATB014, VATB017 (100mg/10mL) which were distributed to hospitals, wholesalers and distributors nationwide from February 2014 through February 2015.  Atracurium Besylate Injection, USP, 50mg/5mL and 100mg/10mL is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation, and is supplied in single-dose and multi-dose vials.

Customers are being notified by fax, email, FedEx, and/or certified mail that includes arrangements for return of all recalled product.Customers have been instructed to examine their inventory immediately and to quarantine, discontinue distribution of and return the recalled lots of product. Customers who may have further distributed this product have been requested to identify their customers and notify them at once of this product recall.

 
[Close]